Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Duletić-Načinović, Antica; Gačić, Vedrana; Valković, Toni; Lučin, Ksenija; Fišić, Elizabeta; Žuvić-Butorac, Marta; Seili-Bekafigo, Irena; Jonjić, Nives

doi:10.1159/000444624

Cited by 33 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several studies on the role of TAMs in DLBCL. TAMs remodel extracellular matrix (ECM) remodeling and promote angiogenesis through producing matrix metalloprotein-9 (MMP-9), legumain, and vascular endothelial growth factor (VEGF) [25, 26]. Reactive oxygen species (ROS) from TAMs contributes to DLBCL progression and drug resistance by increasing the expression of CD44 [27].…”

Section: Discussionmentioning

confidence: 99%

Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count

Zhi-hu²,

Xian

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundDiffuse large B-cell lymphoma (DLBCL) is characterized by its clinical and biological heterogeneity. The clinical prognostic implications of tumor-associated macrophages (TAMs) in DLBCL remain controversial and the correlation between TAMs and peripheral absolute monocyte count (AMC) has not yet been elucidated.MethodsIn 221 untreated, newly diagnosed patients with DLBCL, we evaluated the prognostic value of TAMs using immunohistochemical analysis, as well as the association of TAMs and AMC.ResultsWe found that high CD68 or high CD163 expression was correlated with clinicopathological characteristics, high CD163 expression was an adverse predictor for both overall survival (OS) [hazard ratio (HR) = 2.265, P = 0.005] and progression- free survival (PFS) (HR = 1.925, P = 0.017) in patients with DLBCL. Patients with high CD68 or high CD163 expression had significantly poorer OS and PFS than those with low CD68 or low CD163 expression, respectively (CD68: OS: P<0.001, PFS: P<0.001; CD163: OS: P<0.001, PFS: P<0.001), even in the rituximab era. Moreover, high-risk patients could be further identified by the expression of CD68 or CD163, especially in those classified as low/intermediate risk by International Prognostic Index (IPI). Furthermore, the significant positive correlation was also detected between CD68 expression or CD163 expression and AMC (r = 0.256, P<0.001; r = 0.303, P<0.001).ConclusionsPatients with high expression of TAMs tend to have poorer OS and PFS, even in the rituximab era, and have positive correlation with AMC. Therefore, the peripheral AMC is a useful prognostic marker reflecting the status of the tumor microenvironment (TME) in DLBCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count

Zhi-hu²,

Xian

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…OPN gene is upregulated in primary central nervous system lymphomas (PCNSL) as compared to that in diffuse large B cell lymphoma (DLBCL) [208], and its levels in cerebrospinal fluid (CSF) appear to be an independent predictor of shorter progression-free and overall survival [209]. Serum levels of OPN also predict response to therapy and survival in DLBCL [210, 211] and serum and CSF levels were correlated to tumor bulk and response to therapy in children with acute lymphoblastic leukemia (ALL) [211]. Expression of OPN is increased in both bone marrow blasts and serum of patients with acute myeloid leukemia (AML), and high-OPN mRNA expression independently predicts overall survival ( p = 0.025), especially in low-intermediate risk forms [212].…”

Section: Osteopontin In Hematopoietic and Lymphoid Tumorsmentioning

confidence: 99%

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Castello

Raineri

Salmi

et al. 2017

Mediators of Inflammation

139

132

View full text Add to dashboard Cite

Complex interactions between tumor and host cells regulate systemic tumor dissemination, a process that begins early at the primary tumor site and goes on until tumor cells detach themselves from the tumor mass and start migrating into the blood or lymphatic vessels. Metastatic cells colonize the target organs and are capable of surviving and growing at distant sites. In this context, osteopontin (OPN) appears to be a key determinant of the crosstalk between cancer cells and the host microenvironment, which in turn modulates immune evasion. OPN is overexpressed in several human carcinomas and has been implicated in inflammation, tumor progression, and metastasis. Thus, it represents one of the most attracting targets for cancer therapy. Within the tumor mass, OPN is secreted in various forms either by the tumor itself or by stroma cells, and it can exert either pro- or antitumorigenic effects according to the cell type and tumor microenvironment. Thus, targeting OPN for therapeutic purposes needs to take into account the heterogeneous functions of the multiple OPN forms with regard to cancer formation and progression. In this review, we will describe the role of systemic, tumor-derived, and stroma-derived OPN, highlighting its pivotal role at the crossroads of inflammation and tumor progression.

show abstract

“…Se han asociado niveles elevados en pacientes con estadio avanzado Ann Arbor, IPI > 3 e infiltración en médula ósea. 49,50 Factor derivado de células estromales 1 (SDF-1)…”

Section: Factor De Crecimiento Endotelial Vascular (Vegf)unclassified

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

Sosa-Quintero,

Barreno-Rocha,

Guzmán-Silahua

et al. 2023

Salud Jalisco

View full text Add to dashboard Cite

Los linfomas pertenecen a un grupo de neoplasias que se originan de la proliferación maligna de los linfocitos. Globocan reporta que, en México, el linfoma no Hodgkin (LNH) ocupa el undécimo lugar en nuevos casos con 5,174 al año, así como el undécimo lugar en fallecimientos con 2,741 al año, con una prevalencia a los cinco años de 14,189 casos. A través del tiempo, varios índices pronósticos fundamentados en las características clínicas del paciente han permitido establecer el perfil pronostico basado en factores identificados, que posibilitan implementar estrategias de tratamiento. Los estudios moleculares permiten identificar nuevos biomarcadores relacionados con los linfomas a nivel genético, epigénetico y proteómico, así como en el microambiente tumoral. La aplicación de tecnologías de secuenciación de nueva generación ofrece la oportunidad para la detección de nuevos biomarcadores moleculares implicados en los mecanismos fisiopatológicos de la linfomagénesis, que permiten mejorar la clasificación, el diagnóstico y el pronóstico. Ante la emergencia de numerosos biomarcadores existe el reto de seleccionar aquellos que pueden ser aplicables y reproducibles en la práctica clínica para validarlos e identificar su costo-efectividad. La interacción dinámica de los diferentes factores involucrados en el desarrollo, evolución y pronóstico de los linfomas, además de la aplicación adecuada de biomarcadores, facilitará la transición a una medicina personalizada en pacientes con linfoma.

show abstract

Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Cited by 33 publications

References 47 publications

Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count

Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

Contact Info

Product

Resources

About